Abbott Announces New Test for the Management of Patients with Diabetes
The new fully-automated assay measures glycated hemoglobin (HbA1c), the recommended test to monitor diabetic patients in the laboratory
Abbott Park, Illinois ( ) — More than 346 million people worldwide are living with diabetes, and the World Diabetes Foundation estimates that number will increase by nearly 27 percent by 2030.
In order to help physicians appropriately monitor treatment efficacy for these patients, Abbott announced today CE Marking (Conformité Européenne) for the Abbott ARCHITECT HbA1c (IA) Assay.
Glycated hemoglobin, also known as HbA1c, is a form of hemoglobin used primarily to monitor long-term diabetes control.
This helps physicians understand how well the patient's diabetes is being managed from a treatment or dosing perspective.
The HbA1c test differs from a patient-administered blood glucose test, which takes a snapshot of a patient's blood sugar level at a moment in time.
Laboratories are seeing an increase of HbA1c testing volumes worldwide due to the rise in patients with diabetes.
The Abbott ARCHITECT HbA1c assay is a fully automated chemiluminescent immunoassay to help laboratories manage the increased demand and offer rapid results to physicians.
With a simple blood test, the Abbott ARCHITECT HbA1c (IA) Assay provides a result to the physician in just 36 minutes.
It also demonstrates a good correlation to the gold standard (high performance liquid chromatography), which provides confidence in the accuracy and reproducibility of patient results.
"Abbott's ARCHITECT HbA1c (IA) Assay allows for consistent and accurate testing of HbA1c," said Brian Blaser, executive vice president, Diagnostics Products, Abbott.